To overview |
|
| | |||
| Changes in management |
| Carl Zeiss Meditec reorganises management of its strategic business units | Downloads and Links | ||
| Dr. Ludwin Monz takes over Ophthalmic Systems business unit – Thomas Simmerer new Head of Neuro/ENT Surgery – James L. Taylor to leave company and assume a consulting role for CZM | RTF Documents
english (505 KB)Further Information 
Deutsche Version
| ||
| JENA/Germany, 15.09.2008. Medical technology supplier Carl Zeiss Meditec AG, listed in the TecDAX at the German Stock Exchange (ISIN DE0005313704), is expanding the management of its strategic business units. In doing so the company is creating a further important prerequisite for accelerating its expansion course as announced. James L. Taylor, hitherto Head of the SBU Ophthalmic Systems, will be leaving the company for personal reasons on 30 September 2008. He will continue to be available to Carl Zeiss Meditec as a consultant in strategic, organisational and clinical application-related matters. The regional focus will be placed on the US market. With effect from 1 October 2008, Board Member Dr. Ludwig Monz has been appointed new Head of the SBU Ophthalmic Systems. He was previously responsible for the SBU Neuro/ENT Surgery, which he successfully set on a profitable expansion course. In his new position Dr. Ludwig Monz intends to further expand the innovative power of Ophthalmic Systems, which includes diagnostic and therapeutic systems for ophthalmology, thereby securing the long-term success of this business unit. Dr. Ludwig Monz is concurrently handing over the helm of Neuro/ENT Surgery to Thomas Simmerer. Thomas Simmerer joined Carl Zeiss Meditec on 1 September 2008. He has gained broad experience in medical technology, of late at Dräger Medical AG & Co. KG, where he held various managerial positions, most recently serving as head of a business unit. The management of the SBU Surgical Ophthalmology is to remain in the hands of Dr. Christian Müller. He has been responsible for this unit since 2006. During this time he has actively and successfully promoted its expansion and implemented the integration of Acri.Tec. “Mr Taylor has been instrumental in making Carl Zeiss Meditec one of the leading companies in the field of ophthalmology in the past few years. My sincere thanks are due to him for his effort and dedication. I am pleased that Mr Taylor will continue to support us in the role of independent consultant and that we will be able to draw on his experience in future. Furthermore, I am convinced that we are ideally set with our current team to accelerate the proposed realisation of growth potential of Carl Zeiss Meditec,” says Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec. Eva Sesselmann Director Corporate Communications Phone: +49 3641 220-331 Fax: +49 3641 220-112 E-Mail: 
e.sesselmann@meditec.zeiss.comNumber: 0177-2008-ENG OP Number of Words: 417 Number of Signs: 2612 |
|
